AUTHOR INDEX

Adams, A.B., 115
Anderson, R.J., 33
Andreoni, K., 104
Angus, D.C., 151
Ayuse, T., 104

Beloucif, S., 104
Billiar, T.R., 183
Bittner, H.B., 56
Bondy, G., 82
Branch, R.A., 154
Brienza, N., 104

Casula, M.A., 64
Chelluri, L., 154
Chen, E.P., 56
Codazzi, D., 15
Colombo, A., 15

Daniel, S., 174
Delogu, G., 64
Downey, G.P., 136
Ducas, J., 1
Duronio, V., 82

Fukushima, T., 136

Garber, P.J., 1
Gillam, I.C., 82
Gorcsan, John III, 165
Grant, G.A., 78
Gross-Weege, W., 21
Gu, S., 1

Hayashi, S., 82
Heard, S.O., 7
Hock, R., 33
Hogg, J.C., 82
Hudson, L.D., 97

Iapichino, G., 15

Jamdar, S.C., 72

Kellum, J.A., 51
Kendall, S.W.H., 56
Kramer, D.J., 51

Liebert, S., 21
Linden, P.K., 151
Losser, M.-R., 183

Magder, S., 165
Mancini, P., 64
Marini, J.J., 115
Mirow, N., 21

Nahum, A., 115
Neidhardt, H., 21

O'Donnell, C.P., 104

Pasetti, G., 15
Pastor, C.M., 183
Payen, D.M., 183
Perkins, M., 7
Piantadosi, C.A., 122
Pinsky, M.R., 51, 151
Prewitt, R.M., 1

Quan, S.F., 97

Radrizzani, D., 15
Ravenscraft, S.A., 115
Remick, D.G., 198
Robotham, J., 104
Romand, J.-A., 165
Ronzoni, G., 15
Russell, J.A., 78

Savioli, M., 15
Schick, U., 1
Schneider, M., 21
Sherrill, D.L., 97
Signore, L., 64
Soo, E., 72
Stanko, Ronald T., 165
Steinhorn, D.M., 45
Sue-A-Quan, A., 136

Takata, M., 104
Taylor, D.E., 122
Tellan, G., 64
Tielemans, C., 27
Toth, I., 7
Traver, G.A., 97
Tyler, M.L., 97

Van Trigt, P., 56
Vincent, J.-L., 27

Waddell, T.K., 136
Weiss, M., 21
Weissman, C., 72
Wernet, P., 21

SUBJECT INDEX

Acute phase protein response, endotoxin and, 186-187
Acute Physiology and Chronic Health Evaluation. *See* APACHE II
Acute renal failure (ARF), prevention in ICU, 33-41
Adaptor molecules, 83
Adrenergic agents, interference with plasma catecholamine measurement, 72-76
Adrenocorticotrophic hormone (ACTH), after brain death, 59
Aerobic metabolism, alterations in sepsis, 125-129
Amino acids, endotoxin and, 187
Aminoglycoside nephrotoxicity, prevention in ICU, 33-37
Anion gap, correlation with strong ion gap, 51-55
Antisense inhibition, 147
Aortic pressure, effects on coronary artery flow and coronary thrombolysis, 1-6
APACHE II
  HA-1A for gram-negative sepsis, 158-159
  oscillating therapy for critical illness, 98-102
APACHE II (*Continued*)
  single *vs.* divided aminoglycoside dosage, 35
ARF (acute renal failure), prevention in ICU, 33-41

Bacteria detoxification, endotoxin and, 188-189
Bioassays, cytokine, 209-210
BN50739, for LPS-induced myocardial depression, 8-11
Brain death
  diagnosis, 58-59
  endocrine/metabolic changes, 56-62
  evaluation, 57-58
  validation, 58-59

Canine model
  aortic pressure effects on coronary thrombosis, 1-6
  brain death, endocrine/metabolic changes, 56-62
  hemodynamics of pyruvate infusion, 165-172
  inspiratory tidal volume sparing effects of tracheal gas insufflation, 115-121

AUTHOR INDEX

Adams, A.B., 115
Anderson, R.J., 33
Andreoni, K., 104
Angus, D.C., 151
Ayuse, T., 104

Beloucif, S., 104
Billiar, T.R., 183
Bittner, H.B., 56
Bondy, G., 82
Branch, R.A., 154
Brienza, N., 104

Casula, M.A., 64
Chelluri, L., 154
Chen, E.P., 56
Codazzi, D., 15
Colombo, A., 15

Daniel, S., 174
Delogu, G., 64
Downey, G.P., 136
Ducas, J., 1
Duronio, V., 82

Fukushima, T., 136

Garber, P.J., 1
Gillam, I.C., 82
Gorcsan, John III, 165
Grant, G.A., 78
Gross-Weege, W., 21
Gu, S., 1

Hayashi, S., 82
Heard, S.O., 7
Hock, R., 33
Hogg, J.C., 82
Hudson, L.D., 97

Iapichino, G., 15

Jamdar, S.C., 72

Kellum, J.A., 51
Kendall, S.W.H., 56
Kramer, D.J., 51

Liebert, S., 21
Linden, P.K., 151
Losser, M.-R., 183

Magder, S., 165
Mancini, P., 64
Marini, J.J., 115
Mirow, N., 21

Nahum, A., 115
Neidhardt, H., 21

O'Donnell, C.P., 104

Pasetti, G., 15
Pastor, C.M., 183
Payen, D.M., 183
Perkins, M., 7
Piantadosi, C.A., 122
Pinsky, M.R., 51, 151
Prewitt, R.M., 1

Quan, S.F., 97

Radrizzani, D., 15
Ravenscraft, S.A., 115
Remick, D.G., 198
Robotham, J., 104
Romand, J.-A., 165
Ronzoni, G., 15
Russell, J.A., 78

Savioli, M., 15
Schick, U., 1
Schneider, M., 21
Sherrill, D.L., 97
Signore, L., 64
Soo, E., 72
Stanko, Ronald T., 165
Steinhorn, D.M., 45
Sue-A-Quan, A., 136

Takata, M., 104
Taylor, D.E., 122
Tellan, G., 64
Tielemans, C., 27
Toth, I., 7
Traver, G.A., 97
Tyler, M.L., 97

Van Trigt, P., 56
Vincent, J.-L., 27

Waddell, T.K., 136
Weiss, M., 21
Weissman, C., 72
Wernet, P., 21

SUBJECT INDEX

Acute phase protein response, endotoxin and, 186-187
Acute Physiology and Chronic Health Evaluation. *See* APACHE II
Acute renal failure (ARF), prevention in ICU, 33-41
Adaptor molecules, 83
Adrenergic agents, interference with plasma catecholamine measurement, 72-76
Adrenocorticotrophic hormone (ACTH), after brain death, 59
Aerobic metabolism, alterations in sepsis, 125-129
Amino acids, endotoxin and, 187
Aminoglycoside nephrotoxicity, prevention in ICU, 33-37
Anion gap, correlation with strong ion gap, 51-55
Antisense inhibition, 147
Aortic pressure, effects on coronary artery flow and coronary thrombolysis, 1-6
APACHE II
  HA-1A for gram-negative sepsis, 158-159
  oscillating therapy for critical illness, 98-102
APACHE II (*Continued*)
  single *vs.* divided aminoglycoside dosage, 35
ARF (acute renal failure), prevention in ICU, 33-41

Bacteria detoxification, endotoxin and, 188-189
Bioassays, cytokine, 209-210
BN50739, for LPS-induced myocardial depression, 8-11
Brain death
  diagnosis, 58-59
  endocrine/metabolic changes, 56-62
  evaluation, 57-58
  validation, 58-59

Canine model
  aortic pressure effects on coronary thrombosis, 1-6
  brain death, endocrine/metabolic changes, 56-62
  hemodynamics of pyruvate infusion, 165-172
  inspiratory tidal volume sparing effects of tracheal gas insufflation, 115-121

Canine model (*Continued*)
oxygen consumption in neuroblockade *vs.* sedation, 45-49
Carbohydrate metabolism, in sepsis, 187-188
Carbon substrate metabolism, in sepsis, 125-127
Catecholamines
after brain death, 59-61
plasma level measurements, synthetic adrenergic agents and, 72-76
CAVH (continuous arterio-venous hemofiltration), 27-28
CAVHD (continuous arterio-venous hemodiafiltration), 27, 28
cDNA (complementary DNA), 138
CD14 receptor, 85
Cells. *See also specific types of cells*
interaction with LPS during sepsis, 199
organization, 136-137
signal transduction, 199-200
Chemotactic factors, release from Kupffer cells, 189-190
α-Chloralose oxygen consumption, *vs.* neuromuscular blockade, 45-49
Clinical study design, cost effectiveness of HA-1A for gram-negative sepsis and, 154-163
Coding strand, 87
Complementary DNA (cDNA), 86, 138
Complementary pairing, 138
Continuous hemodiafiltration
arterio-venous, 27, 28
veno-venous, 27, 28
Continuous hemofiltration
arterio-venous, 27-28
for severe sepsis, 27-31
Coronary artery perfusion pressure, coronary artery flow and, 1-6
Cost analyses, of HA-1A for gram-negative sepsis, clinical study design and, 154-163
Critical care medicine, research for, 151-153
Critical illness, continuous oscillation for, 97-102
Cushing reflex, after brain death, 60-61
CVVHD (continuous veno-venous hemodiafiltration), 27, 28
Cytochrome P-450, cytokines and, 188
Cytokine(s). *See also specific cytokines*
acute phase protein response in liver and, 186-187
antibody inhibition of, 207-208
assays, 136
cytochrome P-450 and, 188
endogenous inhibitors, 206
extracellular oxidative stress and, 124
infections and, 201-202
local *vs.* systemic, 204
measurements, 208-210
mechanism of action, 204-205
production, 203-204
release from Kupffer cells, 189
signal transduction and, 82-85
Cytokine receptors, 205-206

Diabetes insipidus, after brain death, 60-61
DNA
amplification, 139-140
DNA (*Continued*)
complementary pairing, 138
detection, 141, 142
genetic manipulations, 146-148
genomic, organization of, 137-138
libraries, 140
recombinant, 136, 202-203
structure, 86-87
DNA ligases, 138-139
Dobutamine
effect on canine hemodynamics *vs.* pyruvate, 165-172
retention time of, 74-75
Dopamine, after brain death, 59

ELISA. *See* Enzyme-linked immunoabsorbent assay (ELISA)
Endocrine changes, after brain death, 56-62
Endothelial cells, in endotoxin-induced hepatotoxicity, 191
Endotoxin
amino acids and, 187
antibodies, 79
bacteria detoxification and, 188-189
hepatic receptors and, 185-186
isolated perfused liver and, 184-185
local/systemic effects in skeletal muscle, 174-181
signal transduction and, 186
ureagenesis and, 187
Enzyme-linked immunoabsorbent assay (ELISA)
for cytokine measurement, 208-209
for protein detection, 143-144
Ephedrine, retention time of, 75-76
Esmolol, retention time of, 75-76
Euthyroid sick syndrome, 62

Filgrastim, neutrophil function enhancement, 21-25
FMLP (N-formyl-methionyl-leucyl-phenylalanine), 21
Free-fatty acids, metabolism, in sepsis, 125-127

Gas exchange, during ventilation, glucose and insulin effects on, 15-20
Gene
detection, 140-146
manipulations, 146-148
structural, 87
therapy, 148-149
Gene products
detection, 140-146
manipulations, 146-148
Genomic DNA
detection, 141
organization, 137-138
Glomerular filtration rate (GFR), aminoglycoside nephrotoxicity and, 34-35
Glucagon, after brain death, 59-60
Glucocorticoid receptor elements (GREs), 88-89
Glucose
effects on injured ventilated patients, 15-20
metabolism, in sepsis, 187-188

Gram-negative sepsis
  cost-effectiveness of human anti-endotoxin antibody, 154-163
  shock prediction in, 64-70
Granulocyte-stimulating factor (GSF), 21
GREs (glucocorticoid receptor elements), 88-89
Growth factors, signal transduction, 82-85
Guinea pigs, LPS-induced myocardial depression, PAF in, 7-13

HA-1A (human anti-endotoxin antibody), cost-effectiveness projections for gram-negative sepsis, 154-163
HAMA (human anti-mouse antibodies), 207-208
Hematocrit, after brain death, 59, 60
Hemodynamics
  after brain death, 58-59
  of liver, in venous and arterial vascular waterfalls, 104-113
  neuromuscular blockade, 48-49
  pyruvate infusion in dogs and, 165-172
  of skeletal muscle, endotoxin and, 174-181
Hemofiltration, continuous
  historical aspects, 27
  techniques, 27-28
Hepatic receptors, endotoxin and, 185-186
Hepatocyte interactions, in sepsis, 191-192
Histones, 87
Hormone responsive elements, 88
Hormones, changes after brain death, 59, 60
Hospitalization time, continuous oscillation for critical illness and, 97-102
Human anti-endotoxin antibody (HA-1A), cost-effectiveness projections for gram-negative sepsis, 154-163
Human anti-mouse antibodies (HAMA), 207-208

ICU. *See* Intensive care unit (ICU)
Immunoassays, cytokine, 208-209
Immunomodulating therapy, randomized clinical trials, 79
Immunoprecipitation, for protein detection, 144, 145
Infections, cytokines and, 201-202
In situ hybridization, 143
Insulin, effects on injured ventilated patients, 15-20
Intensive care unit (ICU)
  enhancement of neutrophil function for sepsis prophylaxis, 21-25
  prevention of drug-induced nephrotoxicity in, 33-41
Interleukin-1, 201
Interleukin-2 receptor, for prediction of shock in gram-negative sepsis, 64-70
Interleukin receptors, 205-206
Introns, 87
Isoproterenol, retention time of, 74-76

JAK2 kinase, 200

Ketone bodies, sepsis and, 188
Kidney failure. *See* Acute renal failure (ARF)
Knock-out, gene, 147
Koch's postulates, 80
Kupffer cells
  functions, in sepsis, 188-191
  interaction with hepatocytes, 191-192

Labetalol, retention time of, 74-75
Leukocyte count kinetics, in postoperative/posttraumatic patients, 21-25
Lipopolysaccharide (LPS)
  myocardial depression, platelet-activating factor in, 7-13
  in sepsis, 198-201
Liver
  blood flow, vascular waterfalls and, 104-113
  injury, during sepsis, 183-193
LPS. *See* Lipopolysaccharide (LPS)
Lung injury, inspiratory tidal volume sparing effects of tracheal gas insufflation, 115-121

MAP (mitogen-activated protein), 200
Mechanical ventilation
  gas exchange, glucose and insulin effects on, 15-20
  inspiratory tidal volume sparing effects of tracheal gas insufflation, 115-121
Mediators. *See also specific mediators*
  antibodies, 146
  in endotoxemia, 78
  extracellular oxidative stress and, 124
  hepatic circulation changes in sepsis and, 185
  molecular biology, 79
  removal by continuous hemofiltration, benefits of, 28-31
  synthesis, 92-93
Messenger RNA, 87, 137, 203
Metabolic acidosis, after brain death, 59-60
Mitogen-activated protein (MAP), 200
MODS (multiple organ dysfunction syndrome), 122, 124
Molecular biology
  application to critical care medicine, 148-149
  of cell response in sepsis, 203-204
  cellular physiology and, 136-138
  cytokine investigations, 202-203
  future, 149
  of sepsis. *See under sepsis*
Monoclonal antibodies, 148, 207-208
Multiple organ dysfunction syndrome (MODS), 122, 124
Myocardial depression, LPS-induced, platelet-activating factor in, 7-13

Natural inhibitors of sepsis, 78-79
Neopterin, for prediction of shock in gram-negative sepsis, 64-70
Nephrotoxicity
  aminoglycoside, 33-37
  NSAID-associated, 37-39
  radiographic contrast agent, 39-41
Neuromuscular blockade
  hemodynamic effects, 48-49
  vs. sedation, 45-49
Neutrophils. *See also* Polymorphonuclear neutrophils (PMNs)
  extrahepatic, interaction with hepatocytes, 191-192
  FMLP-induced chemiluminescence, filgrastim and, 21-25
Nitric oxide, hepatic circulation changes in sepsis and, 185
Nonsteroidal anti-inflammatory drugs (NSAIDs), renal syndromes, 37-39
Norepinephrine
  after brain death, 59

Norepinephrine (*Continued*)
aortic pressure increases, coronary flow and, 1-6
retention time of, 74-75
Northern blotting, 142, 143
Nucleosomes, 87

Oscillating therapy, outcome in critical illness and, 97-102
Oxygen
metabolism, in sepsis, 127-129
supply dependency, in sepsis, 123-124
Oxygen consumption
in neuroblockade *vs.* sedation, 45-49
of skeletal muscle, endotoxin and, 174-181
in ventilation, glucose and insulin effects on, 15-20
Oxygen radicals
assay, 22-23
prevention, filigrim for, 21-25
production in sepsis, 122, 124
release in sepsis, 190-191
tissue injury in sepsis and, 129-131
zymosan-induced, 21-22

PAF (platelet-activating factor), in LPS-induced myocardial depression, 7-13
Parenchymal cells, in sepsis, 185-188
Phenylephrine, epinephrine quantitation and, 72-76
Platelet-activating factor (PAF), in LPS-induced myocardial depression, 7-13
Platelet-activating factor receptor antagonists, for LPS-induced myocardial depression, 7-13
PMNs. *See* Polymorphonuclear neutrophils (PMNs)
Polymerase chain reaction (PCR), 139-140
Polymorphonuclear neutrophils (PMNs)
isolation, 22
sequestration into liver in endotoxemia, 189-190
Porcine liver, portal venous and arterial vascular waterfalls in, 104-113
Posttranslational modifications, of proteins, 144-146
Pro-inflammatory mediators. *See* Mediators
Promoter regions, 87
Propranolol
effect on canine hemodynamics *vs.* pyruvate, 165-172
retention time of, 75-76
Protein(s)
detection, 142, 143
posttranslational modifications, 144-146
recombinant binding, 148
translation, 90-91
transport, 91-93
Protein kinase C, 200
Pyruvate, infusions, effects on canine hemodynamics, 165-172

Radiographic contrast agents, nephrotoxicity, 39-41
Radioimmunoassay, for protein detection, 143
Randomized clinical trials (RCTs)
design, cost-effectiveness of HA-1A for gram-negative sepsis and, 154-163
of immunomodulating therapy, 79
Reactive oxygen species (ROS). *See* Oxygen radicals

Receptors, 148
cytokine, 205-206
hepatic, endotoxin and, 185-186
interleukin-2, for prediction of shock in gram-negative sepsis, 64-70
Recombinant binding proteins, 148
Recombinant DNA
cytokines and, 202-203
techniques, 138-140, 148
Recombinant human granulocyte colony-stimulating factor (rhG-CSF), neutrophil function enhancement, 21-25
Recombinant tissue plasminogen activator (rtPA), low aortic pressure and, 1-6
Renal failure, acute. *See* Acute renal failure (ARF)
Research, critical care medicine, 151-153
Restriction enzymes, 138-139
Restriction fragment length polymorphism (RFLP), 141
Retroviruses, 137
Reverse transcriptase polymerase chain reaction, 142
RFLP (restriction fragment length polymorphism), 141
rhG-CSF (recombinant human granulocyte colony-stimulating factor), neutrophil function enhancement, 21-25
Ribonucleases, 87
Ribosomal RNA, 87, 88
RNA, 137
complementary pairing, 138
detection, 142, 143
genetic manipulations, 146-148
messenger, 87
ribosomal, 87, 88
transcription and, 87-90
RNA polymerases, 87, 137
rtPA (recombinant tissue plasminogen activator), low aortic pressure and, 1-6

Second messengers, 85
Sedation, *vs.* neuromuscular blockade, 45-49
Sense strand, 147
Sepsis
aerobic metabolism alterations, 125-129
carbohydrate metabolism in, 187-188
circulatory paradigms, 122-123
continuous hemofiltration for, 27-31
extracellular oxidative stress and, 124
gram-negative. *See* Gram-negative sepsis
hepatocyte interactions in, 191-192
ketone bodies and, 188
lipopolysaccharide in, 198-201
liver injury during, 183-193
mediators. *See* Mediators
molecular mechanisms, 78-80
mortality, 78
oxygen supply dependency, 123-124
prophylaxis, filigrim for, 21-25
syndrome, 122
tissue injury, intracellular oxidative stress and, 129-131
tissue oxygenation, 123-124
Serpentine receptors, 85
Shock
prediction, in gram-negative sepsis, 64-70
septic, mortality of, 78

Signal transduction
  cellular, 199-200
  endotoxin and, 186
  molecular mechanisms, 82-85
  nuclear, 200
SIG (strong ion gap), calculation, 51-55
Skeletal muscle, endotoxin effects on, 174-181
Southern blotting, 142, 143
SR27417, for LPS-induced myocardial depression, 8-13
Src homology 2 (SH2) domain, 83
SRI63-441, for LPS-induced myocardial depression, 8-11
Strong ion gap (SIG), calculation, 51-55

TATA box, 88
Thyroxine, after brain death, 62
Tissue oxygenation, in sepsis, 123-124
Tracheal gas insufflation, inspiratory tidal volume sparing effects of, 115-121
Transcription, 87-90, 137
Transcription factors, 84, 85
Translation, 90-91, 137
Transport, protein, 91-93
Tricarboxylic acid cycle (TCA), in sepsis, 125
Triiodothyronine, after brain death, 62

Tumor necrosis factor-alpha (TNF-α)
  randomized controlled trials, 79
  role in liver during endotoxemia, 189-190
  synthesis, 92-93
Tumor necrosis factor (TNF)
  antibodies, 146
  assays, 136
  cytotoxicity, 128
  infections and, 201-202
  mechanism of action, 203-204
  production of, 199
  receptors for, 205-206
  removal by continuous hemofiltration, benefits of, 28-31
  synthesis, 203-204
Tyrosine kinase, 83, 200

Urea excretion, glucose and insulin effects on injured ventilated patients and, 15-20
Ureagenesis, endotoxin and, 187

Vascular waterfall, portal venous *vs.* arterial, in porcine liver, 104-113
Vasopressin, after brain death, 59, 61
Vecuronium, oxygen consumption, *vs.* sedation, 45-49
Ventilation. *See* Mechanical ventilation

Western blotting, 142, 143

Zinc fingers, 88